Efficient expression of self-complementary AAV in ganglion cells of the ex vivo primate retina by Koilkonda, Rajeshwari D. et al.
Efficient expression of self-complementary AAV in ganglion cells
of the ex vivo primate retina
Rajeshwari D. Koilkonda,1,2 William W. Hauswirth,3 John Guy1,2
1Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami, FL; 2McKnight Vision Research Center,
University of Miami, Miller School of Medicine, Miami, FL; 3University of Florida, College of Medicine, Gainesville, FL
Purpose: To evaluate the efficiency of self-complementary adeno-associated virus (scAAV)-mediated gene expression
of green fluorescent protein (GFP) or the allotopic human ND4 subunit of complex I in ganglion cells of the primate retina.
Methods: ScAAV2 containing the cDNA encoding the humanized GFP or allotopic ND4 subunit of complex I under the
control of the cytomegalovirus (CMV) immediate early gene enhancer and short chicken beta-actin promoter-exon1-
intron1 (CBA) was injected into the vitreous cavity of five primate eyes after enucleation. Following incubation in standard
Dulbecco's Modified Eagle Medium (DMEM) culture media overnight at 37 °C with 5% CO2, retinal flat mounts were
probed with monoclonal GFP or FLAG antibodies overnight followed by counterstaining with anti-mouse IgG conjugated
to cy2. For identification of retinal ganglion cells (RGCs), the retinal whole mounts were also stained with a Brn3a or
Thy1.2 (protein expressed in RGCs. domain) antibody, then counterstained with cy3 or cy2. Immunofluorescence and
colocalization were assessed using confocal microscopy. Quantitative analysis of GFP, ND4FLAG, Brn3a, or Thy1.2
expressing cells was performed using Image J software.
Results:  While  the  endogenous  fluorescence  of  GFP  was  seen  in  a  few  retinal  cells,  GFP  and  ND4FLAG
immunofluorescence was plentiful. The immunosignals were restricted to the inner retina and colocalized to slightly more
than half of all cells expressing Brn3a or Thy1.2, suggesting efficient expression in RGCs.
Conclusions: Our findings suggest that the hybrid CMV enhancer-CΒA promoter can play an efficient role in targeting
primate RGCs following intravitreal gene delivery using the scAAV2 vector. Donated ex vivo primate eyes may serve as
a model system for testing RGC expression before in vivo intravitreal injections of this and perhaps other AAV serotypes.
Studies  evaluating  ganglion  cell  and  optic  nerve
expression using the adeno-associated virus (AAV) vector for
gene delivery have mostly been performed in cultured human
cells [1,2] or in rodent species [3,4]. For the most part, these
studies have used the chicken beta-actin promoter to drive
transgene expression. This promoter and the AAV vector have
been  successfully  used  for  photoreceptor  gene  expression
when delivered by subretinal injections [5]. Most reports that
have described AAV-mediated gene delivery in nonhuman
primates have used subretinal injections of AAV [6-11]. One
of  these  also  studied  intravitreal  injections,  but  did  not
demonstrate expression of the transgene (VEGF) in retinal
ganglion cells (RGCs) [7]. We were unable to find published
data showing that intravitreal injections of AAV target RGCs
of nonhuman primates.
Last year Merigan and coworkers [12] presented data
showing  that  intravitreal  injections  of  standard  single-
stranded (ss) AAV serotype 2 (ssAAV2) using the chicken β-
actin (CBA) promoter did not drive expression of GFP in
RGCs,  but  rather  in  foveal  cones.  Since  intravitreal  gene
delivery to RGCs is central to our mitochondrial gene therapy
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studies of patients with Leber Hereditary Optic Neuropathy
(LHON)  [13]  and  optic  neuritis  [14],  we  evaluated  the
efficiency  of  the  CBA  promoter  used  successfully  in  our
rodent studies [3,13,15,16] to drive reporter green fluorescent
protein (GFP) gene expression in the primate eye and further
to characterize whether expressed protein was localized to
RGCs.
METHODS
Viral preparation: The humanized gene for GFP (GeneBank
U50963)  was  inserted  into  a  self-complementary  AAV
(scAAV) vector (regulated by the 381 bp cytomegalovirus
(CMV)  immediate  early  gene  enhancer  /578  bp  CBA
promoter-exon1-intron1).  Plasmids  were  amplified  and
purified by cesium chloride gradient centrifugation and then
packaged into AAV-2 capsids by transfection into human 293
cells  using  standard  procedures  [17].  Vector  preparations
were produced by the plasmid cotransfection method. The
crude  iodixanol  fraction  [17],  as  described,  was  further
purified and concentrated by column chromatography on a
5 ml HiTrap Q Sepharose column using a Pharmacia AKTA
FPLC system (Amersham Biosciences, Piscataway, NJ). The
vector was eluted from the column using 215 mM NaCl, pH
8.0, and the recombinant adeno-associated virus (rAAV) peak
collected. Vector-containing fractions were then concentrated
and buffer exchanged in Alcon Balanced Salt Solution (Bss;
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2796Alcon Laboratories, Fort Worth, TX) with 0.014% Tween-20,
using  a  Biomax  100  K  concentrator  (Millipore,  Billerica,
MA).  Vector  was  then  titered  for  DNase-resistant  vector
genomes by real-time PCR relative to a standard [17]. Finally,
the purity of the vector was validated by silver-stained sodium
dodecyl  sulfate–PAGE,  assayed  for  sterility  and  lack  of
endotoxin  (endotoxin-PTS  rapid  endotoxin  detection  kit,
Charles River), and then aliquoted and stored at −80 °C. The
resultant  rAAV-packaged  GFP  or  allotopic  human
ND4FLAG virus preparation contained 1011 to 1012 vector
genome-containing particles per milliliter.
AAV  and  flat-mount  retina  preparation:  The  anterior
segments were carefully removed. Next 10 μl of scAAV-
CBA-GFP was injected into the vitreous of three eyes that had
been enucleated from two rhesus macaque by Dr. Jonathan
Horton  (University  of  California,  San  Francisco,  CA)
approximately 12 h earlier. We then injected 10 μl of scAAV-
CBA-ND4FLAG into two donor cynomolgus monkey eyes,
received  from  Dr.  Jean-Marie  Parel  (Bascom  Palmer  Eye
Institute), within 20–30 min of enucleation. After incubation
in  standard  Dulbecco’s  Modified  Eagle  Medium  culture
media overnight at 37 °C with 5% CO2, retinas were gently
separated  from  the  eyecups.  Flat-mounted  retinas  were
prepared and laid out with the RGC layer facing upward. The
tissue was blocked and permeabilized with 20% goat serum,
0.2% Triton X-100 in PBS (10×, 1.37 M NaCl, 0.027 M KCl,
and 0.119 M Phosphate Buffer, pH 7.4) for 30 min at room
temperature.  This  was  followed  by  immunostaining  with
mouse monoclonal GFP or FLAG primary antibody for 12 h
at 4°C. Primary antibody solution is routinely contained in
10% goat serum and 0.2% Triton X-100 in PBS, pH 7.4. The
tissues were then washed and incubated in secondary antibody
with the fluorolink cy2 (AAV-GFP-inoculated eyes) or cy3
(AAV-ND4FLAG-inoculated  eyes)  conjugated  goat  anti-
mouse IgG at room temperature for 2 h in PBS containing 10%
goat serum and 0.2% Triton X-100. The tissue was washed
with  PBS  and  observed  with  the  Zeiss  Axiovert  200M
Fluorescence/Live cell Imaging Microscope (Carl Zeiss Inc.,
Thornwood, NY). Further, for identifying the retinal cells that
were positive for GFP or FLAG, the retinal whole mounts
were washed again, permeabilized in the aforedescribed same
manner and incubated in primary antibody Brn3a or Thy1.2
in PBS, pH 7.4 with 10% goat serum and 0.2% Triton X-100,
at 4 °C for 12 h. The retinal tissues were washed (washed twice
and  done  at  room  temperature-RT)  and  incubated  in
secondary antibody cy3 (AAV-GFP inoculated eyes) or cy2
(AAV-ND4FLAG  inoculated  eyes)  conjugated  goat  anti-
mouse IgG at room temperature for 2 h in PBS containing 10%
goat serum and 0.2% Triton X-100. The tissue was washed
with PBS and observed for fluorescence with a Leica TCS SP5
confocal microscope. The retinas were then cryoprotected in
sucrose buffers and snap frozen. Cryo-sections counterstained
with DAPI were examined for immunofluorescence. Velocity
software  was  used  to  assess  colocalization  of  GFP  or
ND4FLAG to Brn3a- or Thy1.2-expressing pixels and Image
J  software  was  used  for  quantitative  analysis  of  GFP-  or
ND4FLAG-expressing  cells  to  Brn3a-  or  Thy1.2-positive
RGCs.
RESULTS
scAAV-GFP: Fluorescence microscopy of retinal flat mounts
inoculated  with  scAAV-GFP  revealed  GFP-positive  cells
(Figure 1A). Confocal microscopy of retinal flat mounts from
eyes  injected  with  scAAV-GFP  revealed  that  GFP
immunofluorescence was plentiful (Figure 1B). RGCs labeled
with the Brn3a antibody are shown in Figure 1C. The merged
images  revealed  that  GFP-expressing  cells  colocalized
exclusively with those expressing Brn3a (Figure 1D), thus
confirming that GFP expression occurred in primate RGCs.
As indicated by the absence of cells that were labeled only
green in panels 1D, we were unable to visualize any GFP-
expressing cells that did not also express Brn3a. In addition,
as indicated by many red labeled cells, not all Brn3a-positive
RGCs expressed GFP. Higher power confocal micrographs of
scAAV-GFP-injected eyes showed nuclei labeled by DAPI
(Figure 1E). Cells expressing GFP (Figure 1F) or Thy1.2
(Figure 1G) colocalized (Figure 1H). Cryosectioned retinas of
scAAV-GFP-injected  eyes  counterstained  with  DAPI
revealed the nuclei of cells in the RGC layer, inner nuclear
layer,  or  outer  nuclear  layer  (Figure  1I).  The  GFP
immunofluorescence was seen exclusively in the ganglion cell
layer (Figure 1J), in which RGCs were labeled by Thy1.2
(Figure 1K). Colocalization of GFP and Thy1.2 cells is shown
in  the  merged  panel  (Figure  1L).  Control  cross-sections
counterstained with DAPI (Figure 2A) without the primary
anti-GFP  antibody  that  were  counterstained  with  the
secondary antibody showed no GFP signal (Figure 2B). DAPI
stained the RGC layer (Figure 2C) of a specimen that was
double-labeled for GFP (Figure 2D) and Thy1.2 (Figure 2E).
The merged panel (Figure 2F) shows Thy1.2-labeled RGCs
that were negative for GFP.
scAAV-ND4FLAG:  Confocal  microscopy  of  a  retinal  flat
mount  from  an  eye  injected  with  the  scAAV-ND4FLAG
packaged in VP3 capsids with the tyrosine to phenylalanine
transition at amino acid position 444 reveals many cells were
labeled  with  the  anti-FLAG  antibody  (Figure  3A).  RGCs
expressing Thy1.2 are shown in Figure 3B. Colocalization of
ND4FLAG- and Thy1.2-expressing cells are shown in the
merged panel (Figure 3C), thus indicating that most cells
expressing  the  ND4FLAG  fusion  protein  were  RGCs.
Confocal imaging of longitudinal cross-sections of the retina
revealed ND4FLAG immunofluorescence within the RGC
layer  (Figure  3D).  Immunofluorescent  labeling  of  Thy1.2
cells with cy2 was somewhat fading by the time of confocal
imaging of cryosectioned retina (Figure 3E). However, the
merged  panel  also  counterstained  with  DAPI  showed
ND4FLAG  immunofluorescence  within  the  RGC  layer
(Figure  3F).  The  opposite  eye  injected  with  scAAV-
Molecular Vision 2009; 15:2796-2802 <http://www.molvis.org/molvis/v15/a295> © 2009 Molecular Vision
2797ND4FLAG but packaged with the standard VP3 capsids with
intact tyrosine residues showed no labeling with the anti-
FLAG antibody (data not shown).
Efficiency of GFP and ND4FLAG expression: We compared
the number of cells that were immunopositive for either GFP
or ND4FLAG to the number of ganglion cells as identified by
Brn3a or Thy1.2 immunoreactivity. There were 486 GFP-
positive cells/40 mm2  relative to 805 Brn3a-positive RGCs /
40 mm2 (n=2) and 174 GFP-positive cells/40 mm2  relative to
293 Thy1.2-positive cells/40 mm2 (n=1). Similarly, there were
225 FLAG-positive cells/40 mm2  relative to 293 Thy1.2-
positive cells/40 mm2 (n=1). Thus the efficiency of allotopic
and xenotypic expression in the ex vivo primate was possibly
as high as about 60%.
DISCUSSION
Last  year  Merigan  and  coworkers  [12]  presented  data
suggesting  that  in  vivo  intravitreal  injections  of  ssAAV
serotype  2  using  the  chicken  beta-actin  promoter  did  not
efficiently drive expression of GFP in RGCs, but resulted in
GFP expression in foveal cones of the primate eye. We show
here that when injected into the vitreous of the ex vivo primate
eye, the hybrid CMV enhancer-CΒA promoter, successfully
Figure 1. Fluorescence Microscopy GFP. Retinal flat mounts inoculated with scAAV-GFP revealed some green fluorescent protein (GFP)
positive cells (A). Confocal microscopy revealed many more GFP positive cells by immunofluorescence (B). RGCs labeled with the Brn3a
antibody (C) and merged images revealed GFP expressing cells co-localized exclusively with those expressing Brn3a (D). Higher power
confocal micrographs of scAAV-GFP injected eyes show nuclei labeled by DAPI (E). Cells expressing GFP (F) or Thy1.2 (G) co-localized
(H). Cryo-sectioned retinas of scAAV-GFP injected eyes counterstained with DAPI revealed the nuclei of cells in the retinal ganglion cell
layer (RGC), inner nuclear layer (INL) or outer nuclear layer (ONL; I). GFP immunofluorescence is seen exclusively in the ganglion cell
layer (J) whose RGCs were labeled by Thy1.2 (K). Colocalization of GFP and Thy1.2 cells is shown in the merged panel (L).
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2798Figure  2.  Fluorescence  microscopy
controls.  Retinal  cross-sections
counterstained with DAPI (A) without
the  primary  anti-green  fluorescent
protein  (GFP)  antibody  that  were
counterstained  with  the  secondary
antibody showed no GFP labeling (B).
DAPI  stained  RGC  layer  (C)  from
specimen double-labeled for GFP (D)
and Thy1.2 are shown (E). The merged
image  of  panels  C-E  shows  Thy1.2
RGCs  without  GFP  positivity  (F).
Abbreviations:  ONL  represents  outer
nuclear  layer,  INL  represents  inner
nuclear  layer,  RGC  represents  retinal
ganglion cell. Scale bar equals to 50 µm.
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2799used in rodents, efficiently drives GFP expression in ganglion
cells of the nonhuman primate retina. These are the very cells
affected by LHON [18]. The ssAAV2 has been used safely in
a phase I human ocular gene therapy trial [19]. Newer AAV
vectors  such  as  the  scAAV  that  contains  complementary
strands for delivery [20-22] or other AAVs with mutations in
the  capsid  proteins  designed  to  reduce  cellular  AAV
degradation [23,24] that may provide the promise of higher
levels of efficiency of transgene expression have not been
tested in the primate retina until now. We showed here that
the  allotopic  ND4  subunit  of  complex  I  delivered  by  a
scAAV2 is expressed in primate RGCs with an efficiency
comparable to that of GFP delivered by an ssAAV2 in our
rodents.
The robust expression of transgene in RGCs only 12 h
after vector injection deserves comment. We used a scAAV
vector  rather  than  the  standard  single-stranded  version.
Deletion of 25 bases in the 3′ region of the forward terminal
repeat of AAV results in generation of an AAV containing
both complementary strands [21,22]. It is generation of the
complementary strand of ssAAV that is believed to be the rate-
limiting step in expression from standard ssAAV vectors and
leads  to  the  several  week  delay  in  transgene  expression
typically seen from ssAAV vectors in vivo. A scAAV like the
one used here resulted in transgene expression of GFP within
days  after  injection  in  rodents  [25,26].  Why  would  such
rapidity of expression be important clinically? Increasing the
speed  of  ND4  gene  expression  may  be  relevant  to  the
treatment of LHON patients who have acute visual loss that
Figure 3. Fluorescence microscopy ND4FLAG. Confocal microscopy of a retinal flat mount from an eye injected with the scAAV-ND4FLAG
packaged in VP3 capsids with the tyrosine to phenylalanine transition at position 444 revealed many cells were labeled with the anti-FLAG
antibody (A). RGCs expressing Thy1.2 (B) colocalized with ND4FLAG expressing cells are shown (C). Confocal imaging of longitudinal
cross-sections of the retina revealed ND4FLAG immunofluorescence within the RGC layer (D). Immunofluorescent labeling of Thy1.2
positive cells with cy2 was somewhat fading by the time of confocal imaging of cryosectioned retina (E). A merged panel counterstained with
DAPI shows ND4FLAG immunofluorescence within the RGC layer (F). Abbreviations: INL represents inner nuclear layer, RGC represents
retinal ganglion cell. Scale bar equals to 50 µm.
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2800must be treated quickly [1,2,16]. We found GFP expressed as
early as four days after intraocular injection of mice with the
scAAV-GFP, while taking approximately two weeks with
ssAAV-GFP  in  a  parallel,  equal  titer  experiment.  With
scAAV-GFP the efficiency of RGC labeling was not only
faster  but  it  was  superior  to  ssAAV.  Rescue  of  optic
neuropathy in the rodents [27] suggests that allotopic ND4
gene therapy may be effective in LHON patients with the
G11778A  mitochondrial  DNA  mutation.  Our  expression
studies using the AAV vector in the primate eye suggest that
the  AAV  cassette  will  result  in  transgene  expression  in
humans.
Recently it has been shown that AAV vectors with capsid
mutations may further increase transgene expression in RGCs
[25]. These vectors were constructed based on the finding that
a  key  limiting  factor  in  AAV  transduction  efficiency  is
phosphorylation of tyrosine residues exposed on the vector
capsid  surface.  Normally  this  leads  to  ubiquination  and
proteosomal degradation of vector before its genome can be
delivered to the cell nucleus [28]. Petrs-Silva and coworkers
[25] have been testing this idea in the mouse retina using Tyr-
Phe (Y-F) mutations at several surface tyrosine residues in
AAV  serotype  2,  8,  and  9  vectors.  Using  a  self-
complementary CBA-GFP vector insert, they quantified a 10–
15-fold enhancement in RGC GFP expression compared to
the  corresponding  wild-type  parent  for  each  serotype,
including  AAV2  used  here,  four  weeks  after  intravitreal
injection of equal titers of AAV vectors. While one of these
mutants (tyrosine to phenylalanine substitution at amino acid
444 of the VP3 capsid) produced the highest levels of GFP
fluorescence, the intravitreal injections of high titer virus also
resulted in labeling of retinal cells other than RGCs. Reducing
viral titers confined GFP expression to RGCs. We showed
here that scAAV-ND4FLAG packaged with this mutant VP3
had an efficiency of RGC expression in the primate retina of
60% comparable to that of GFP.
For testing approaches to augmenting potency applicable
to optic neuropathy, we believe that donated ex vivo primate
eyes  may  serve  as  a  platform  for  modulating  transgene
expression in RGCs as a prelude to in vivo studies of living
nonhuman primates and eventually human gene therapy trials.
Rose and coworkers have also found that the cultured primate
retina  survives  days  after  enucleation  and  that  it  is  an
extremely useful model system for evaluations of RGC and
axonal  regeneration  [29].  It  is  highly  likely  that  optic
neuropathy patients selected for gene therapy trials will have
mild  or  moderate  degrees  of  RGC  or  axonal  injury  from
LHON or optic neuritis, with the axotomized retina employed
here probably representing the most severe form of injury
[30].
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